Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$1.12

0.00 (0.00%)

High$1.15
Low$1.11
Volume0
Market Cap$15,977,260

12/07/18  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $1.12 with a 52 week high of $11.43 and a 52 week low of $0.83.

Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update

12/03/18

Read More

Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

11/08/18

Read More

Gemphire Therapeutics Announces Workforce Reduction

09/24/18

Read More


There are currently no events scheduled.